Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza - Wikidata - wikimedia - TriplyDB

Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza

Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza

http://www.wikidata.org/entity/Q24647051

about

H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP Weighing serological evidence of human exposure to animal influenza viruses - a literature review Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses.Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects.The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and direct MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza.Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel.Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus.Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection.Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial.Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans.Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.Seroconversion to seasonal influenza viruses after A(H1N1)pdm09 virus infection, Quebec, Canada Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza.Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine Profiling of humoral response to influenza A(H1N1)pdm09 infection and vaccination measured by a protein microarray in persons with and without history of seasonal vaccination.Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial Population-level antibody estimates to novel influenza A/H7N9.Protective measures and H5N1-seroprevalence among personnel tasked with bird collection during an outbreak of avian influenza A/H5N1 in wild birds, Ruegen, Germany, 2006 Evidence that life history characteristics of wild birds influence infection and exposure to influenza A viruses.Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies.Human H5N2 avian influenza infection in Japan and the factors associated with high H5N2-neutralizing antibody titer.Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine.Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza.Cross-reactivity between avian influenza A (H7N9) virus and divergent H7 subtypic- and heterosubtypic influenza A viruses A novel M2e-multiple antigenic peptide providing heterologous protection in mice.Immunogenetics of seasonal influenza vaccine response Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases.

P2860

Q21090076-5D230236-1515-48BF-88B3-180BB3A87E4E Q21090975-DB9357B8-F7A3-435D-BA3D-8F5039AC62CB Q28075317-41EE7D13-B6C5-4D1D-A67A-4A3517E745DC Q30363454-AFD15999-C142-41B9-9144-76202AB18089 Q30366119-2D522E71-E28C-4020-A814-167C6581F2EC Q30368645-AC79496D-AF77-402B-B8A4-E292C3CBA6D0 Q30373391-41963055-408A-4309-A76C-94F5EA9FAC03 Q30374764-6566C02D-05CF-4D92-AADF-518491CDB8F2 Q30376727-CE48F565-05A1-468B-8661-1FCED47FCEEF Q30384441-9712E4EB-9F91-4E62-BBDE-0D2B79EBFFCB Q30388038-133EBFF2-2751-44E1-A28E-96EC5C30CF1E Q30389669-D0D29016-191A-4267-A08E-B19E6DD64481 Q30394896-B7FE3B49-8791-4FBF-AF93-04641C08921A Q30396693-E748CE55-4AF1-46BF-B5AC-BAE8B6A86828 Q30400133-E871509B-797F-4DCC-9A44-DBAE9DC89A13 Q30401056-026BC8E3-1A52-4D44-BE63-D109EEB9FC8F Q30401306-EFAC8FB0-9F4A-4ED6-BB6B-EB9510D0602E Q30401524-330FCA8C-DAA0-45FD-AD00-2D870F28B8F8 Q30403078-ADB22740-1457-4C4B-9B5C-8646570FDA97 Q30403507-0891489B-75EA-43C7-AED4-DC10B48A54DC Q30414543-86F787C5-BA2C-4A08-A396-E55691B0119C Q30418193-0E089A07-536C-4604-B79F-B1DCB92E5A49 Q30424161-71CA8C3B-1520-4BCE-B93F-9D5F978CDDD3 Q30425194-383827F8-10D8-40D4-81ED-944F9C11E0D9 Q30425439-457F584F-2521-49A9-9605-2AFD336E5F8C Q30426571-BEC28105-F41E-40B4-AD5B-07E65AA6EBCC Q30429009-AEBB4097-0F82-44D3-B340-1A8DEAE2EC51 Q30430737-696C1B4C-FC32-4039-B44C-3D4406BDE199 Q33511049-ED1E3BFE-3253-41D2-873A-CC6A23070830 Q34613129-8C4E08AC-BCDC-4F1B-BB7B-8CE17FC6167D Q34756837-6462C133-7C2D-4E0D-A14C-6F1D1CE60C2D Q34792746-A6A10B4F-03DC-4771-BF4B-426FA4377546 Q34869353-E5832FE3-96EF-4EF8-BF5B-921FF8D57B5E Q36075789-C4B5DAFA-14DC-4B8A-BFB1-F7AD8621037F Q36151974-AB67E618-2894-4458-BB6F-D6A594EBD01E Q36251479-A9937834-0F00-423E-8F8D-00B5EC3E26E4 Q36611283-87045347-9533-4177-BC29-6395C2E53881 Q36731466-5E75F67D-BA5D-4EB9-970C-CAB300A56F91 Q37030332-D200F6CF-9C6C-4165-95B9-0930E02C2F20 Q37398991-78B06409-FA2B-4900-9642-ACE5087798D8

P2860

Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza

http://www.wikidata.org/entity/Q24647051

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Cross-subtype immunity against ...... ently vaccinated for influenza

@ast

Cross-subtype immunity against ...... ently vaccinated for influenza

@en

Cross-subtype immunity against ...... ently vaccinated for influenza

@nl

type

label

Cross-subtype immunity against ...... ently vaccinated for influenza

@ast

Cross-subtype immunity against ...... ently vaccinated for influenza

@en

Cross-subtype immunity against ...... ently vaccinated for influenza

@nl

prefLabel

Cross-subtype immunity against ...... ently vaccinated for influenza

@ast

Cross-subtype immunity against ...... ently vaccinated for influenza

@en

Cross-subtype immunity against ...... ently vaccinated for influenza

@nl

P1433

Q24647051-2D6460B2-00CF-4B0D-B0AE-EF72E51FD094

P1476

Q24647051-07D24ED8-16F9-48B1-9A16-1A6E89FB92CB

P2093

Q24647051-36795EC1-8934-423A-B1DD-590B2C879353

Q24647051-5374993A-ABF8-488E-BC70-080D0E25BFEA

Q24647051-55AC6135-84F0-498F-B118-B5198CF0623E

Q24647051-71B34EF3-C967-40B7-B2AE-1FCD94B2CD10

Q24647051-A295324D-8099-4AAC-B10B-0ADB69B3934A

Q24647051-B3D24593-F246-4291-A2C1-BD482FC470B1

Q24647051-CBA6692E-E24E-46C5-84C9-9D1CB2DF48E7

Q24647051-F1384B4E-6C62-42BF-BB18-CE9439FE0757

P2860

Q24647051-116305CF-7088-4EE5-910C-EF6362F91862

Q24647051-13A8D645-0EBB-4D4A-8E65-74B749014E1C

Q24647051-16859FC1-BB31-4B6F-B57C-10DE7EAB3836

Q24647051-19BB65EE-6622-45C0-8B58-2B84D4437369

Q24647051-1B808653-287C-4568-B2B5-A057ACAE59C9

Q24647051-202A4BA6-59A7-40FA-BC98-94C5E44ACDA8

Q24647051-2BD2A4FC-A8EE-4C30-AD5F-CF374D1B8431

Q24647051-3F7F492C-D437-4286-A5DD-AF78D39CA088

Q24647051-4D8D14D0-D29E-437F-A640-98FF866BA411

Q24647051-523A0E9D-5803-471D-AAC7-0C35686B9320

P304

Q24647051-3221E13A-AD8B-44B5-AB98-0BC3A1F0A710

P31

Q24647051-F82B1C4B-8ECE-4AA0-AA6A-6DE68CB8EF13

P3181

Q24647051-11E87B59-1818-49A8-8835-23E75FE16235

P356

Q24647051-E3D60EEC-421F-420B-BB7D-5CDB02EBF1B2

P407

Q24647051-19FCABC2-B485-410E-A1C4-F32D9969D447

P433

Q24647051-0AB14E38-A65C-4E76-9C4D-4E22E209ABCC

P478

Q24647051-5AA5C1C8-6523-4127-9057-4A1FAB3153B4

P50

Q24647051-3DF1F254-9088-4AEB-A76B-350B8C88BC18

Q24647051-76131E5F-8D12-4388-A3F4-0DD8B92EB06D

Q24647051-8C032BF5-3A7A-4570-A790-CF4B0D0425D6

Q24647051-D66429F0-536C-4223-8FAB-67B053F6986A

P577

Q24647051-9675AFEA-2408-49A8-B976-FA40B060F90D

P5875

Q24647051-2D9DBB5D-718B-4B56-B51A-11E25D5CF806

P698

Q24647051-D0868DF8-9D6B-4CF7-9C52-32A1ABA3E393

P921

Q24647051-D9D039F1-520A-4F58-B377-E20F46612EC4

P932

Q24647051-52F996C9-EA4B-4F39-849A-38AD204AA403

P3181

P356

P1433

Emerging Infectious Diseases

P1476

Cross-subtype immunity against ...... ently vaccinated for influenza

@en

P2093

Cristiana Gioia

http://www.w3.org/2001/XMLSchema#string

Fabrizio Poccia

http://www.w3.org/2001/XMLSchema#string

Maria R Capobianchi

http://www.w3.org/2001/XMLSchema#string

Massimo Tempestilli

http://www.w3.org/2001/XMLSchema#string

Paola Piacentini

http://www.w3.org/2001/XMLSchema#string

Roberta Chiappini

http://www.w3.org/2001/XMLSchema#string

Salvatore Squarcione

http://www.w3.org/2001/XMLSchema#string

Vincenzo Puro

http://www.w3.org/2001/XMLSchema#string

P2860

Influenza pandemics of the 20th century

Avian influenza A (H5N1) age distribution in humans

Global epidemiology of influenza: past and present.

Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

Human cytotoxic T-lymphocyte repertoire to influenza A viruses.

Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets.

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

T cell-dependent B cell activation.

Trends and epidemics of influenza and pneumonia: 1918-1951

P304

121-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2672143

http://www.w3.org/2001/XMLSchema#string

P356

10.3201/EID1401.061283

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Ippolito

Concetta Castilletti

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5594291

http://www.w3.org/2001/XMLSchema#string

P698

18258091

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

P932

2600140

http://www.w3.org/2001/XMLSchema#string